A 30-week randomized non-inferiority study comparing 2 mg once-weekly EX-LAR with 10 g twice-daily EX in 295 patients with T2DM
The country's expanding private healthcare sector demonstrates willingness to adopt new obesity pharmacotherapy despite high treatment costs
We promptly initiated a review and have been in direct and ongoing communication with the patient to reach a resolution
If you're taking a GLP-1 and notice symptoms such as fatigue, dizziness, or dry mouth, dehydration may be one possible cause
Potential adverse effects and drug interactions: Gastrointestinal symptoms Cramping, diarrhoea, constipation, and abdominal discomfort are common, particularly at higher doses
The SELECT cardiovascular outcomes trial established that semaglutide reduces major adverse cardiovascular events by 20%, providing a strong clinical rationale for treatment that extends beyond weight management alone